Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Uncontrolled Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)
NCT04678856Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis without nasal polyps (CRSsNP) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Lund Mackay Score at 24 weeks. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis without nasal polyps (CRSsNP)
Beyond the preview
Go deeper on NCT04678856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678856.